|
|
||||||||
1. The further purification of a polypeptide having potent enterogastrone activity, without CCKPZ effects, is described.
2. The material was inhibitory when doses of 1·0 µg/kg.hr were administered intravenously. Amino acid analyses demonstrated the absence of proline, a high content of glutamine and a preponderance of lysine over arginine. Tryptic degradation destroys the inhibitory effect of the polypeptide. Further studies must be performed before the physiological status of the polypeptide can be ascertained.
This article has been cited by other articles:
![]() |
J. J. Meier, O. Goetze, J. Anstipp, D. Hagemann, J. J. Holst, W. E. Schmidt, B. Gallwitz, and M. A. Nauck Gastric inhibitory polypeptide does not inhibit gastric emptying in humans Am J Physiol Endocrinol Metab, April 1, 2004; 286(4): E621 - E625. [Abstract] [Full Text] [PDF] |
||||
![]() |
A Ballinger Gastric inhibitory polypeptide links overnutrition to obesity Gut, March 1, 2003; 52(3): 319 - 320. [Full Text] [PDF] |
||||
![]() |
R. J. Bollag, Q. Zhong, P. Phillips, L. Min, L. Zhong, R. Cameron, A. L. Mulloy, H. Rasmussen, F. Qin, K. H. Ding, et al. Osteoblast-Derived Cells Express Functional Glucose-Dependent Insulinotropic Peptide Receptors Endocrinology, March 1, 2000; 141(3): 1228 - 1235. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Kieffer and J. Francis Habener The Glucagon-Like Peptides Endocr. Rev., December 1, 1999; 20(6): 876 - 913. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |